Ascendis Pharma A (ASND) Equity Income (2019 - 2025)
Historic Equity Income for Ascendis Pharma A (ASND) over the last 7 years, with Q3 2025 value amounting to -$8.8 million.
- Ascendis Pharma A's Equity Income fell 8284.44% to -$8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$46.3 million, marking a year-over-year decrease of 13161.85%. This contributed to the annual value of -$21.7 million for FY2024, which is 20969.99% down from last year.
- Per Ascendis Pharma A's latest filing, its Equity Income stood at -$8.8 million for Q3 2025, which was down 8284.44% from -$4.6 million recorded in Q2 2025.
- Over the past 5 years, Ascendis Pharma A's Equity Income peaked at -$1.2 million during Q2 2022, and registered a low of -$33.9 million during Q1 2021.
- Over the past 5 years, Ascendis Pharma A's median Equity Income value was -$5.7 million (recorded in 2024), while the average stood at -$8.1 million.
- As far as peak fluctuations go, Ascendis Pharma A's Equity Income crashed by 192709.27% in 2021, and later skyrocketed by 8386.8% in 2022.
- Ascendis Pharma A's Equity Income (Quarter) stood at -$8.5 million in 2021, then grew by 3.95% to -$8.1 million in 2022, then soared by 61.27% to -$3.1 million in 2023, then plummeted by 55.4% to -$4.9 million in 2024, then crashed by 79.37% to -$8.8 million in 2025.
- Its Equity Income stands at -$8.8 million for Q3 2025, versus -$4.6 million for Q2 2025 and -$28.0 million for Q1 2025.